Cavrotolimod

Cat. No.:	HY-139785	
CAS No.:	2378664-12-9	
Molecular Formula:	$C_{_{300}}H_{_{423}}N_{_{71}}O_{_{161}}P_{_{26}}S_{_{23}}$	
Molecular Weight:	9142.88	Cavrotolimod
Target:	Toll-like Receptor (TLR)	Caviolonnou
Pathway:	Immunology/Inflammation	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	

BIOLOGICAL ACTIVITY

Description Cavrotolimod is an immunostimulatory spherical nucleic acid (SNA) modified with type B CpG oligonucleotides designed to agonize TLR9 and elicit immune responses useful in oncology applications.

REFERENCES

[1]. Daniel WL, Lorch U, Mix S, Bexon AS. A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation. Front Immunol. 2022;13:1073777.

[2]. Rubatto M, Sciamarrelli N, Borriello S, et al. Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer. Front Med (Lausanne). 2023;9:959289.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Product Data Sheet

